Por favor, use este identificador para citar o enlazar este documento: https://hdl.handle.net/2445/179214
Título: Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
Autor: Cantón, Rafael
Loza, Elena
Arcay, Ricardo M.
Cercenado, Emilia
Castillo, Francisco Javier
Cisterna, Ramón
Gálvez Benítez, Lidia
González Romo, Fernando
Hernández Cabezas, Alicia
Rodríguez Lozano, Jesús
Suárez Barrenechea, Ana Isabel
Tubau, Fe
Díaz Regañón, Jazmín
López Mendoza, Diego
SMART-Spain Working Group
Materia: Pseudomonas
Resistència als medicaments
Medicaments antibacterians
Epidemiologia
Pseudomonas
Drug resistance
Antibacterial agents
Epidemiology
Fecha de publicación: 1-mar-2021
Publicado por: Sociedad Española de Quimioterapia
Resumen: Objective: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods: The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.
Nota: Reproducció del document publicat a: https://doi.org/10.37201/req/019.2021
Es parte de: Revista Española de Quimioterapia, 2021, vol. 34, num. 3, p. 228-237
URI: https://hdl.handle.net/2445/179214
Recurso relacionado: https://doi.org/10.37201/req/019.2021
ISSN: 0214-3429
Aparece en las colecciones:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Archivos de este documento:
Archivo Descripción DimensionesFormato 
canton01mar2021.pdf493.5 kBAdobe PDFMostrar/Abrir


Este documento está sujeto a una Licencia Creative Commons Creative Commons